U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

[riky]

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

By David Morgan WASHINGTON (Reuters) - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. It would be sold under the name Saxenda if approved for obesity by the FDA. The FDA typically follows the recommendations of its advisory panels.

Source: You are not allowed to view links. Register or Login